Kyowa Kirin.
pharmaceutical company
- Reports this week
- 0
- Active events
- 1
- Connections
- 53
What's happening
Active this week
Earlier this month
One to three months ago
-
Kyowa Kirin, Eli Lilly, Kura Oncology, and others are forming a new company to focus on menin inhibitors for disease, involving investment and shared operational teams.Some support1 report
-
Kyowa Kirin conducts business in the Americas, US, and Japan markets.Some support1 report
-
Manufacturers committed to a $19.6B US manufacturing investment and contributing APIs to national reserves.Some support2 reports
-
Kyowa Kirin, headquartered in Tokyo, is building a new life sciences facility in Sanford, North Carolina.Some support4 reports1 development inside
-
Kyowa Kirin committed to investing in a life sciences facility in Lee County, North Carolina, partnering with Central Carolina Community College and Pfizer.Some support1 report
-
Benchling and Kyowa Kirin are implementing an AI platform for centralized data management and R&D research in Japan.Some support1 report
-
Kura Oncology reported its earnings on Nasdaq on August 12, 2026. Kyowa Kirin announced it was funding Kura's program.Some support4 reports
Gone quiet
No new reports in 90+ days-
FDA granted Breakthrough Therapy Designation to Ziftomenib and entered a global strategic collaboration agreement.Some support4 reports1 development inside
-
The FDA has selected a facility for a PreCheck Pilot Program involving Kyowa Kirin.Some support1 report
-
Angela Williams is the Global Head of Health Economics at Kyowa Kirin, and H. Miles Prince is a Principal Investigator at the Peter MacCallum Cancer Centre.Some support1 report
-
The Cutaneous Lymphoma Foundation collaborated with Kyowa Kirin on studies, presenting data at a Congress in Montreal.Some support1 report
-
Kyowa Kirin and Otsuka Holdings Co., Ltd., two medical companies, are currently competing for investment.Some support2 reports
-
Ardelyx has received FDA-approved treatments and strengthened its global reach through a partnership.Well supported6 reports1 development inside
No events began in the chosen period. Widen it, or reset.
Around Kyowa Kirin this week
News at the entities that move Kyowa Kirin most-
Donald Trump OperationalPakistan pursues crypto diplomacy with a Trump affiliate while establishing a new FIA unit to combat financial crimes.Moves Kyowa Kirin
-
Kura Oncology OperationalKura Oncology announced the commercialization of an FDA-approved drug and began using LinkedIn for company information.Moves Kyowa Kirin
-
FDA StructuralFDA accepted Axion BioSystems' Letter of Intent (LOI) for a neural assay on November 10, 2026.Moves Kyowa Kirin
-
Jefferies Financial Group TransactionalJefferies Financial Group covered a UK-based commercial property company, Landsec, focusing on key urban markets in the UK.Moves Kyowa Kirin
-
Amgen OperationalAmgen announced results from the VESALIUS-CV trial, led by Duke and involving Harvard, at AHA's Scientific Sessions.Moves Kyowa Kirin
-
Cutaneous Lymphoma Foundation OperationalAn EORTC meeting was held in Berlin, where Citius partnered with the Cutaneous Lymphoma Foundation for a workshop.Moves Kyowa Kirin
Connections
The 24 strongest of 53, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Kura Oncology Operational
Kura Oncology and Kyowa Kirin maintain a strategic collaboration for joint development and commercialization of ziftomenib.
-
Donald Trump Operational
Trump's drug plan and associated deals explicitly include Kyowa Kirin as a participant in policy initiatives.
-
Benchling Structural
Benchling provides centralized data management and discovery services utilized by Kyowa Kirin.
-
Angela Williams Structural
Angela Williams serves as the Global Head Health Economics at Kyowa Kirin.
-
Sanford Structural
Kyowa Kirin is establishing a biomanufacturing facility in Sanford, creating a structural dependency.
-
Jefferies Financial Group Transactional
Jefferies Financial Group issued a stock rating downgrade or hold for Kyowa Kirin.
-
Fosun Pharmaceutical Structural
The companies are formally partnered with Ardelyx for therapeutics development.
-
Central Carolina Community College Structural
Kyowa Kirin provides ongoing facility and hub support for Central Carolina Community College.
Show all 24 connections
-
Amgen Operational
Amgen and Kyowa Kirin are engaged in a functional partnership regarding Amgen's product portfolio.
-
FDA Structural
Kyowa Kirin's U.S. manufacturing establishment is subject to FDA regulatory oversight.
-
Cutaneous Lymphoma Foundation Operational
The Foundation engages in active research partnerships with the pharmaceutical company on medical studies.
-
Astellas Pharma Operational
Both companies are active participants in the same market pricing program and US manufacturing investment initiatives.
-
North Carolina Shared context
Kyowa Kirin operates from a facility situated within North Carolina's life sciences sector.
-
Berlin Mentioned together
Kyowa Kirin was involved in a findings presentation held in Berlin.
-
Tokyo Shared context
Kyowa Kirin is a company that operates from its headquarters located in the city of Tokyo.
-
Julia Scarisbrick Operational
Julia Scarisbrick provides support and validation for study findings published by Kyowa Kirin.
-
Princeton Shared context
Kyowa Kirin operates from a location within Princeton, New Jersey.
-
Lee County Transactional
Kyowa Kirin committed to investing in Lee County.
-
Montreal Shared context
The relationship is defined by the location where a study presentation took place.
-
Americas Shared context
Kyowa Kirin conducts business operations within the Americas market.
-
La Jolla Shared context
Kyowa Kirin maintains a research facility within the geographic area of La Jolla, CA.
-
Steris Shared context
Both companies are noted as operating within the same life sciences industry hub.
-
Knight Therapeutics Mentioned together
No direct relationship between Knight Therapeutics and Kyowa Kirin was observed in the provided evidence.
-
Edward Wilson Mentioned together
The provided evidence does not describe a relationship between Edward Wilson and Kyowa Kirin.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
1 eventSeptember 2026
3 events- Jefferies lowered Kyowa Kirin's stock rating on September 1, 2026, for the company headquartered in Tokyo.
- Kyowa Kirin, Eli Lilly, Kura Oncology, and others are forming a new company to focus on menin inhibitors for disease, involving investment and shared operational teams.
- Kyowa Kirin conducts business in the Americas, US, and Japan markets.
Show 2 earlier months
August 2026
4 events- Manufacturers committed to a $19.6B US manufacturing investment and contributing APIs to national reserves.
- Kyowa Kirin committed to investing in a life sciences facility in Lee County, North Carolina, partnering with Central Carolina Community College and Pfizer.
- Benchling and Kyowa Kirin are implementing an AI platform for centralized data management and R&D research in Japan.
- Kura Oncology reported its earnings on Nasdaq on August 12, 2026. Kyowa Kirin announced it was funding Kura's program.
June 2026
7 events- Kyowa Kirin, headquartered in Tokyo, is building a new life sciences facility in Sanford, North Carolina.
- FDA granted Breakthrough Therapy Designation to Ziftomenib and entered a global strategic collaboration agreement.
- The FDA has selected a facility for a PreCheck Pilot Program involving Kyowa Kirin.
- Angela Williams is the Global Head of Health Economics at Kyowa Kirin, and H. Miles Prince is a Principal Investigator at the Peter MacCallum Cancer Centre.
- The Cutaneous Lymphoma Foundation collaborated with Kyowa Kirin on studies, presenting data at a Congress in Montreal.
- Kyowa Kirin and Otsuka Holdings Co., Ltd., two medical companies, are currently competing for investment.
- Ardelyx has received FDA-approved treatments and strengthened its global reach through a partnership.